Clinical Studies
Clostridium Difficile Infection
Clostridium Difficile Infection
This infection may not respond to antibiotic treatment alone in a significant fraction of patients. These patients typically benefit from Fecal Microbiota Transplantation, previously known as bacteriotherapy. 'Microbiota' refers to the entire microbial communities; these can be harvested from fecal material of the donors. We study the effects of this procedure on the microbial composition of fecal samples in the recipients and different aspects of host response to this procedure (PI: Dr. Alexander Khoruts).
For more information contact:
Dr. Alex Khoruts
khoru001@umn.edu
Donor Program
Donor Program
UMN Microbiota Therapeutics Program is recruiting healthy volunteers as donors of fecal material. The donors have to pass rigorous screening and testing to qualify as they need to be absolutely healthy. This is not merely a research program in microbiota therapeutics development, but a life-saving program for many recipients. Please contact fmtstudy@umn.edu if you would like to participate as a donor. (PI: Dr. Alexander Khoruts).
For more information contact:
Dr. Alex Khoruts
khoru001@umn.edu
A Prospective Cohort Study of Interventions for Necrotizing Pancreatitis
A Prospective Cohort Study of Interventions for Necrotizing Pancreatitis
All patients undergoing treatment for necrotizing (severe) acute pancreatitis are enrolled in a prospective database involving types of interventions (endoscopic, radiologic, surgical) to assess outcomes and predictors of outcomes.
For more information contact:
Dr. Marty Freeman
freem020@umn.edu
(612) 625-8999
Evaluation of Belatacept
Evaluation of Belatacept
The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant.
For more information contact:
Dr. John Lake
lakex009@umn.edu
Once-Daily Oral E5501 Tablets
Once-Daily Oral E5501 Tablets
The purpose of this study is to evaluate the efficacy of once-daily Oral E5501 in subjects with chronic liver diseases and thrombocytopenia prior to elective surgical or diagnostic procedures, to evaluate the safety of short-term administration of E5501 and to evaluate the pharmacokinetics (PK) of E5501.
For more information contact:
Dr. John Lake
lakex009@umn.edu
Reversal of Hepatorenal Syndrome Type 1 With Lucassin®
Reversal of Hepatorenal Syndrome Type 1 With Lucassin®
This study is designed to evaluate the efficacy and safety of intravenous Lucassin® (terlipressin) versus placebo for the treatment of type 1 hepatorenal syndrome (HRS) in subjects receiving standard of care albumin therapy.
For more information contact:
Dr. John Lake
lakex009@umn.edu
Clostridium Difficile Infection This infection may not respond to antibiotic treatment alone in a significant fraction of pati
Clostridium Difficile Infection This infection may not respond to antibiotic treatment alone in a significant fraction of pati
This study will assess the safety and efficacy of different doses of sotrastaurin when combined with tacrolimus for the prevention of acute rejection after de novo liver transplantation.
For more information contact:
Dr. John Lake
lakex009@umn.edu
Research ethics at the University of Minnesota
We are committed to protecting research participants, upholding ethical standards, and improving our practice at every step of our work.